Core Viewpoint - Thermo Fisher Scientific is considering selling part of its diagnostics business due to industry concerns over federal spending cuts on research, with a target sale price of around $4 billion [1][2]. Company Summary - The diagnostics unit of Thermo Fisher produces infectious disease testing equipment and is currently under evaluation for potential sale to private equity firms [2][3]. - The company has experienced a 20% decline in its shares this year, while competitors Danaher and Becton, Dickinson and Company have seen declines of 11% and 23%, respectively [4]. - In the first quarter, Thermo Fisher reported a year-over-year organic revenue growth of 1% [4]. - The CEO of Thermo Fisher expressed pride in the company's strong performance amid a challenging macroeconomic environment [5]. Industry Summary - The healthcare sector is facing volatility due to concerns about the impact of federal budget cuts on research funding, particularly cuts proposed by President Donald Trump to the National Institutes of Health [3]. - Becton, Dickinson and Company announced plans to separate its life sciences business, which includes a diagnostics segment, to enhance focus and value [6][7].